OpenLegislation

Paragraph 4 F1

The details of the prescribed product, including where applicable the—

(a)

common name as defined by Article 1 of Directive 2001/83/EC;

(b)

brand name if—

(i)

the prescribed product is a biological medicinal product as referred to in point 3.2.1.1.(b) of Annex 1 (Part 1) to Directive 2001/83/EC; or

(ii)

the prescribing professional deems it medically necessary for that product to be dispensed and, in that case, the prescribing professional’s reasons justifying the use of the brand name;

(c)

pharmaceutical formulation (such as tablet, solution etc.);

(d)

quantity;

(e)

strength as defined in Article 1 of Directive 2001/83/EC; and

(f)

dosage regimen.

Annotations

Textual amendments

F1

Sch. inserted (31.3.2015) by The National Health Service (Cross-Border Health Care) (Scotland) Amendment Regulations 2015 (S.S.I. 2015/91), regs. 1(1), 2(1)(c)